ALOX12: A Potential Drug Target and Biomarker for Diseases (G239)

Target Name: ALOX12

NCBI ID: G239

ALOX12

ALOX12: A Potential Drug Target and Biomarker for Diseases

ALOX12 (12-Lipoxygenase) is a protein that is expressed in various tissues throughout the body, including the skin, heart, liver, and lungs. It is a key enzyme in the synthesis of collagen, a protein that is responsible for the structure and strength of connective tissue. Mutations in the ALOX12 gene have been linked to various diseases, including skin conditions, heart failure, and cancer. As a result, ALOX12 has emerged as a promising drug target and a potential biomarker for several diseases.

The ALOX12 gene is located on chromosome 16 and encodes a protein that consists of 12 subunits. It is a cytoplasmic protein that is primarily localized to the cytoplasm of cells, where it is involved in the synthesis of collagen. Collagen is a complex protein that is composed of multiple subunits that are held together by disulfide bonds. It is responsible for providing structure and support to various tissues in the body, including bones, skin, and connective tissue.

Mutations in the ALOX12 gene have been linked to various diseases, including skin conditions, heart failure, and cancer. For example, mutations in the ALOX12 gene have been linked to the development of conditions such as alopecia areata, a hair loss disorder, and leathery skin disease. In addition, mutations in the ALOX12 gene have also been linked to the development of heart failure and cancer.

As a result, ALOX12 has emerged as a promising drug target and a potential biomarker for several diseases. Researchers are currently working to develop drugs that can target ALOX12 and prevent or reverse the effects of mutations in the gene. These drugs may be used to treat a variety of diseases, including skin conditions, heart failure, and cancer.

In addition to its potential as a drug target, ALOX12 has also been shown to be a potential biomarker for several diseases. The collagen synthesis that is carried out by ALOX12 is a critical step in the development and maintenance of tissues in the body. As a result, changes in the level or structure of collagen in the body can provide valuable information about the health of various tissues.

Research has shown that ALOX12 levels are often reduced in tissues that are affected by diseases, such as cancer and heart failure. This suggests that ALOX12 may be a useful biomarker for these diseases. In addition, some studies have shown that ALOX12 levels are also reduced in skin conditions, such as alopecia areata. This suggests that ALOX12 may be a potential biomarker for these conditions as well.

Furthermore, some researchers have used ALOX12 as a potential drug target in their efforts to develop new treatments for cancer. They believe that by inhibiting the activity of ALOX12, they may be able to kill or slow the growth of cancer cells. This is an important step in the development of new treatments for cancer, as many current treatments are effective only against certain types of cancer.

In conclusion, ALOX12 is a protein that is expressed in various tissues throughout the body and is involved in the synthesis of collagen. Mutations in the ALOX12 gene have been linked to various diseases, including skin conditions, heart failure, and cancer. As a result, ALOX12 has emerged as a promising drug target and a potential biomarker for these diseases. Researchers are currently working to develop drugs that can target ALOX12 and prevent or reverse the effects of mutations in the gene. In addition, ALOX12 has also been shown to be a potential biomarker for several diseases, including skin conditions and cancer.

Protein Name: Arachidonate 12-lipoxygenase, 12S Type

Functions: Catalyzes the regio and stereo-specific incorporation of molecular oxygen into free and esterified polyunsaturated fatty acids generating lipid hydroperoxides that can be further reduced to the corresponding hydroxy species (PubMed:17493578, PubMed:1851637, PubMed:8319693, PubMed:8500694, PubMed:18311922, PubMed:32404334). Mainly converts arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to the specific bioactive lipid (12S)-hydroperoxyeicosatetraenoate/(12S)-HPETE (PubMed:17493578, PubMed:22984144, PubMed:24282679, PubMed:8319693, PubMed:8500694). Through the production of bioactive lipids like (12S)-HPETE it regulates different biological processes including platelet activation (PubMed:8319693, PubMed:8500694). It can also catalyze the epoxidation of double bonds of polyunsaturated fatty acids such as (14S)-hydroperoxy-docosahexaenoate/(14S)-HPDHA resulting in the formation of (13S,14S)-epoxy-DHA (PubMed:23504711). Furthermore, it may participate in the sequential oxidations of DHA ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate) to generate specialized pro-resolving mediators (SPMs) like resolvin D5 ((7S,17S)-diHPDHA) and (7S,14S)-diHPDHA, that actively down-regulate the immune response and have anti-aggregation properties with platelets (PubMed:32404334). An additional function involves a multistep process by which it transforms leukotriene A4/LTA4 into the bioactive lipids lipoxin A4/LXA4 and lipoxin B4/LXB4, both are vasoactive and LXA4 may regulate neutrophil function via occupancy of specific recognition sites (PubMed:8250832). Can also peroxidize linoleate ((9Z,12Z)-octadecadienoate) to (13S)-hydroperoxyoctadecadienoate/ (13S-HPODE) (By similarity). Due to its role in regulating both the expression of the vascular endothelial growth factor (VEGF, an angiogenic factor involved in the survival and metastasis of solid tumors) and the expression of integrin beta-1 (known to affect tumor cell migration and proliferation), it can be regarded as protumorigenic (PubMed:9751607, PubMed:16638750, PubMed:22237009). Important for cell survival, as it may play a role not only in proliferation but also in the prevention of apoptosis in vascular smooth muscle cells (PubMed:23578768)

The "ALOX12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALOX12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets